These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23115117)

  • 21. [Treatment of acute myeloblastic leukemia].
    Jacquillat C; Weil M; Gemon MF
    Therapeutique; 1973 Mar; 49(3):221-5. PubMed ID: 4517257
    [No Abstract]   [Full Text] [Related]  

  • 22. Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia.
    Yanada M; Borthakur G; Ravandi F; Bueso-Ramos C; Kantarjian H; Estey E
    Haematologica; 2008 Aug; 93(8):1263-5. PubMed ID: 18519513
    [No Abstract]   [Full Text] [Related]  

  • 23. [Therapy of non-lymphoid acute leukemias].
    Mandelli F
    Minerva Med; 1975 Jul; 66(51):1546-52. PubMed ID: 1057048
    [No Abstract]   [Full Text] [Related]  

  • 24. [On the consolidation, maintenance and reconsolidation treatment of acute leukemia (author's transl)].
    Masaoka T
    Nihon Ketsueki Gakkai Zasshi; 1974 Oct; 37(5):748-55. PubMed ID: 4533929
    [No Abstract]   [Full Text] [Related]  

  • 25. [Difficulties of remission induction treatment of acute myeloblastic leukemia].
    Fière D; Bryon PA; Martin C; Revol L
    Sem Hop; 1974 May; 50(25):1691-4. PubMed ID: 4369538
    [No Abstract]   [Full Text] [Related]  

  • 26. [Leukemia in advanced age. 1: Acute leukemia].
    Jehn U
    Fortschr Med; 1994 Apr; 112(12):167-71. PubMed ID: 8200603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
    Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
    Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of clonogenic assay for induction and duration of complete remission in acute myelogenous leukemia.
    Marie JP; Zittoun R; Delmer A; Thevenin D; Suberville AM
    Leukemia; 1987 Feb; 1(2):121-6. PubMed ID: 3478535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapeutic evolution of 63 cases of recent acute myeloblastic leukemias].
    Fiere D; Bryon PA; Dechavanne M; Guyon JM; Kahi S; Revol L
    Lyon Med; 1971 Feb; 225(3):225-8. PubMed ID: 5280026
    [No Abstract]   [Full Text] [Related]  

  • 30. A comparative trial of remission induction (by cytosine arabinoside, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia.
    Biomedicine; 1973 May; 18(3):192-8. PubMed ID: 4517790
    [No Abstract]   [Full Text] [Related]  

  • 31. [Diagnostics and therapy of acute myeloid leukemia].
    Kern W; Haferlach T; Schoch C; Hiddemann W
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2208-13. PubMed ID: 12397550
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of acute myelogenous leukaemia in adults. A retrospective study of 70 patients (1968-1973).
    Willemze R; Hartgrink-Groeneveld CA; Speck B; Eernisse JG
    Neth J Med; 1975; 18(1):17-28. PubMed ID: 1055303
    [No Abstract]   [Full Text] [Related]  

  • 33. [Analysis of the effect of cellular morphology on obtaining a complete remission in 99 cases of acute leukemia].
    Ríos A; Rozman C; Del Cañizo MC; Brugués R
    Sangre (Barc); 1984; 29(3):273-9. PubMed ID: 6592764
    [No Abstract]   [Full Text] [Related]  

  • 34. Acute leukemia: early recognition can spell survival.
    Vaughan WP; Karp JE; Burke PJ
    Geriatrics; 1981 Jun; 36(6):32-6. PubMed ID: 6939652
    [No Abstract]   [Full Text] [Related]  

  • 35. [Electron microscopic bone marrow changes in acute leukemias before and after cytosin-arabinoside therapy].
    Ruzicka F; Weigerstorfer B
    Verh Dtsch Ges Inn Med; 1973; 79():369-72. PubMed ID: 4524459
    [No Abstract]   [Full Text] [Related]  

  • 36. Increased tumor growth and drug uptake predicts for response to continuous infusion high-dose cytarabine.
    Burke PJ; Karp JE
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):55-9. PubMed ID: 3859933
    [No Abstract]   [Full Text] [Related]  

  • 37. [Chemotherapy of acute leukemia].
    Gerhartz H
    Dtsch Med Wochenschr; 1967 Dec; 92(52):2371-5. PubMed ID: 5235193
    [No Abstract]   [Full Text] [Related]  

  • 38. Fatal outcome after combined therapy for myeloblastic leukaemia and toxoplasmosis.
    Lancet; 1973 Mar; 1(7805):727. PubMed ID: 4120530
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of acute leukemia by quantitative observation of leukemic cells and normal hematopoietic cells in the bone marrow (author's transl)].
    Oshima T
    Nihon Ketsueki Gakkai Zasshi; 1974 Oct; 37(5):773-4. PubMed ID: 4533931
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical classification and evaluation of treatment response in acute myeloid leukaemia on the basis of differences of leukaemic cell differentiation.
    Brincker H
    Scand J Haematol; 1973; 11(5):383-90. PubMed ID: 4521555
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.